December 11-14, 2021; Atlanta, Georgia
Event-based analyses show that acalabrutinib had a lower incidence, exposure-adjusted incidence, and exposure-adjusted time with events of CV-related toxicities (eg, afib/flutter, hypertension, and bleeding) compared with ibrutinib in this head-to-head phase III trial.